Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kevin Gayout"'
Autor:
Derrick L. Dopkin, Xiaochuan Shan, James L. Riley, Kevin Gayout, Joshua Glover, Rachel S. Leibman, Colby R. Maldini, Joshua P. Mills
Publikováno v:
Molecular Therapy
Mol Ther
Mol Ther
HIV infection preferentially depletes HIV-specific CD4+ T cells, thereby impairing antiviral immunity. In this study, we explored the therapeutic utility of adoptively transferred CD4+ T cells expressing an HIV-specific chimeric antigen receptor (CAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b2a3c9d36f15298a119e3a9abe9d2f4
https://doi.org/10.1016/j.ymthe.2020.05.012
https://doi.org/10.1016/j.ymthe.2020.05.012
Autor:
Leo Li-Ying Chan, Kevin Gayout, Andrea C. Love, Colby R. Maldini, James L. Riley, Timothy D. Smith, Kevin W. Tosh
Publikováno v:
J Immunol Methods
Since the FDA approval of two Chimeric Antigen Receptor (CAR) T cell therapies against CD19(+) malignancies, there has been significant interest in adapting CAR technology to other diseases. As such, the ability to simultaneously monitor manufacturin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d998d66b47f01532717abf92edf1415c
https://doi.org/10.1016/j.jim.2020.112830
https://doi.org/10.1016/j.jim.2020.112830
Autor:
James L. Riley, Andrea C. Love, Leo Li-Ying Chan, Kevin Gayout, Timothy D. Smith, Colby R. Maldini, Kevin W. Tosh
Publikováno v:
Cancer Research. 80:6288-6288
Since the FDA approval of two CAR T cell therapies, Kymriah (Tisagenlecleucel, Novartis) and Yescarta (Axicabtagene ciloleucel, Kite) for CD19+ malignancies, there has been a significant interest for developing new CARs targeting other disease indica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c217ec14122f6d336ce0facc7ef6143
https://doi.org/10.1158/1538-7445.am2020-6288
https://doi.org/10.1158/1538-7445.am2020-6288